Because of no patent protection in India, two generic versions of Acomplia (rimanobant) are being sold in India under the names of Slimona and Rimoslim for as little as $0.14 per pill according to Bloomberb News.

Patients given 20 mg of Acomplia (rimonobant) per day lost an average 15.2 pounds in the Rimonobant In Obesity—Lipids study (RIO-Lipids) according to a review paper about the drug. This compares to 6.7 pounds for those given 5 mg, and 3.3 pounds for those given a placebo.

Patients given 20 mg of Acomplia (rimonobant) per day lost an average 14.5 pounds in the Rimonobant In Obesity—Europe study (RIO-Europe) according to a review paper about the drug. This compares to 7.5 pounds for those given 5 mg, and 4 pounds for those given a placebo.

Patients given 20 mg of Acomplia (rimonobant) per day lost an average 10.3 pounds in the Rimonobant In Obesity—North America study (RIO-North America) according to a review paper about the drug. This compares to 2.9 pounds for those given 5 mg.

Nausea occurs in about 1 out of every 8 or 9 patients (11-13 percent) taking 20 mg of Acomplia (rimonobant) according to a review paper about the drug.

Approximately one-in-eight patients (12.8 percent) given 20 mg of Acomplia (rimonobant), and one-in-eleven (9.4 percent) given 5 mg, withdrew from a drug study due to side effects according to a review paper about the drug.

Depression occurs in 3.7% of patients taking 20 mg of Acomplia (rimonobant) according to a review paper about the drug. In 2.9 percent of patients given 20 mg, the depression was bad enough to withdraw from the study.

Anxiety occurred in 8.7 percent of patients, or about one out of every eleven patients, taking 20 mg, and 2.9 percent taking 5 mg compared to 3.8 percent of those taking a placebo according to a review paper about the drug. The anxiety was bad enough to cause patients to withdraw from the study occurred in 1.7% of patients taking 20 mg of Acomplia (rimonobant) and 0.3 percent taking 5 mg.

Acomplia’s (rimonabant) adverse effects include anxiety and depression according to one paper discouraging the use of the drug.

People taking 20 mg of Acomplia (rimonabant) lost 9.8 pounds more than those taking a placebo after one year and 7.9 pounds more after two years according to a two year study.

On June 21st, 2006, the weight loss and anti-smoking drug Acomplia (rimonabant) was approved for sale in the 25 countries in the European Union.

Acomplia (rimonabant) causes weight loss by both decreasing appetite and increasing thermogenesis according to a study in mice.

Acomplia (rimonabant) will be submitted to the U.S. Food and Drug Administration (FDA) by mid-2005, requesting approval to be sold in the U.S. according to a spokesman for Sanofi-Aventis, the company which makes Acomplia (rimonabant).

People given 20 mg of Acomplia (rimonabant) per day maintained an average weight loss of 15.6 pounds after two years compared to 5.5 pounds for those given a placebo according to a new report from the phase III “Rimonabant in Obesity-Europe Trial”.

Acomplia (rimonabant) causes 10 pounds more weight loss than a placebo according to the results of a one year study published in The Lancet.

The average weight loss is people given Acomplia (rimonabant) is 7.9 pounds for those given 5 mg per day in addition to diet, and 18.9 pounds for those given 20 mg per day.

The most frequent side effects from Acomplia (rimonabant) are nausea, dizziness, and upper respiratory tract infections.

At least forty percent of subjects who have been given 20 mg of Acomplia (rimonabant) per day in addition to a reduced calorie diet have lost more than 10 percent of their body weight.

Acomplia (rimonabant) causes an average weight loss of 19 pounds for two years compared to 5.1 pounds for those given a placebo according to a presentation made at an American Heart Association conference on November 9, 2004.

A drug called Acomplia (rimonabant), which helped people lose 20 pounds and helps smokers stop smoking without gaining weight, may be available in the U.S. in a year or two.